Skip to Content

Generic EpiPen Jr Availability

See also: Generic EpiPen

EpiPen Jr is a brand name of epinephrine, approved by the FDA in the following formulation(s):

EPIPEN JR. (epinephrine - injectable;intramuscular, subcutaneous)

  • Manufacturer: MYLAN SPECIALITY LP
    Approval date: December 22, 1987
    Strength(s): 0.15MG/DELIVERY [RLD]

Has a generic version of EpiPen Jr been approved?

An Authorized Generic version of EpiPen Jr has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.

List of authorized generic versions:

  • Epinephrine INTRAMUSCULAR INJECTION .15 mg/.3mL
    Mylan Specialty L.P.
    NDC Code: 495020101
  • Epinephrine INTRAMUSCULAR INJECTION .3 mg/.3mL
    Mylan Specialty L.P.
    NDC Code: 495020102
  • Epinephrine INTRAMUSCULAR INJECTION .3 mg/.3mL
    A-S Medication Solutions
    NDC Code: 500902733
  • Epinephrine INTRAMUSCULAR INJECTION .15 mg/.3mL
    A-S Medication Solutions
    NDC Code: 500902734
  • Epinephrine INTRAMUSCULAR INJECTION .15 mg/.3mL
    Medical Purchasing Solutions, LLC
    NDC Code: 718727134
  • Epinephrine INTRAMUSCULAR INJECTION .3 mg/.3mL
    Medical Purchasing Solutions, LLC
    NDC Code: 718727135

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of EpiPen Jr. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Automatic injector
    Patent 7,449,012
    Issued: November 11, 2008
    Inventor(s): Young; Matthew Egerton & Raven; Sophie Rebecca & Murphy; Martin Joseph & Hurlstone; Christopher John & Daintrey; Joseph William & Rochford; Craig Malcolm & Kirkwood; Stephen Philip & Mathews; Colin James & Hill; Robert L. & Wilmot; John Glyndwr
    Assignee(s): Meridian Medical Technologies, Inc.

    An auto-injector for dispensing a predetermined dose of medicament is disclosed. The auto-injector includes a needle cover that is configured to move from a retracted position to an extended locked position. The auto-injector includes a first locking assembly to hold the needle cover in a locked retracted position and a second locking assembly to hold the needle cover in a locked extended position.

    Patent expiration dates:

    • September 11, 2025
      ✓ 
      Drug product
  • Automatic injector with kickback attenuation
    Patent 7,794,432
    Issued: September 14, 2010
    Inventor(s): Young; Matthew Egerton & Raven; Sophie Rebecca & Murphy; Martin Joseph & Hurlstone; Christopher John & Daintrey; Joseph William & Rochford; Craig Malcolm & Kirkwood; Stephen Philip & Mathews; Colin James & Hill; Robert L. & Wilmot; John Glyndwr
    Assignee(s): Meridian Medical Technologies, Inc.

    An auto-injector for dispensing a predetermined dose of medicament is disclosed. The auto-injector includes a needle cover operative to engage an injection site. The needle cover is configured to move from a retracted position prior to a medicament dispensing operation to an extended locked position after the medicament dispensing operation. Any residual activation force remaining after the medicament dispensing operation is contained within the auto-injector and is not directed to the needle cover, thus attenuating, if not eliminating, any kickback effect.

    Patent expiration dates:

    • September 11, 2025
      ✓ 
      Drug product
  • Automatic injector with needle cover
    Patent 8,048,035
    Issued: November 1, 2011
    Inventor(s): Mesa; C. Michael & Cors; Sarah Jane & Penney; Melinda Fischer & Tomellini; Dalita Rosemarie & Bremley; Mark Bumb & Wilmot; John Glyndwr & Young; Matthew Egerton & Raven; Sophie Rebecca & Murphy; Martin Joseph & Hurlstone; Christopher John & Daintrey; Joseph William & Rochford;
    Assignee(s): Meridian Medical Technologies, Inc.

    An auto-injector automatically dispenses a predetermined dose of medicament upon activation. The auto-injector includes a needle cover operative to engage an injection site and activate the injector. The needle cover is configured to move from a locked retracted position prior to a medicament dispensing operation to a locked extended position after the medicament dispensing operation. The non-removable needle cover prevents contact with the needle both before and after the medicament dispensing operation.

    Patent expiration dates:

    • September 11, 2025
      ✓ 
      Drug product
  • Automatic injector
    Patent 8,870,827
    Issued: October 28, 2014
    Assignee(s): Meridian Medical Technologies, Inc.

    An automatic injector dispenses a predetermined dose of medicament without a user having to manually force the needle into an injection site. The automatic injector includes a needle cover having a locked retracted position with respect to the injector housing prior to a medicament dispensing operation. The needle cover is operative to engage an injection site prior to a medicament dispensing operation.

    Patent expiration dates:

    • September 11, 2025
      ✓ 
      Drug product
  • Automatic injector with needle cover
    Patent 9,586,010
    Issued: March 7, 2017
    Assignee(s): Meridian Medical Technologies, Inc.

    An auto-injector automatically dispenses a predetermined dose of medicament upon activation. The auto-injector includes a needle cover operative to engage an injection site and activate the injector. The needle cover is configured to move from a locked retracted position prior to a medicament dispensing operation to a locked extended position after the medicament dispensing operation. The non-removable needle cover prevents contact with the needle both before and after the medicament dispensing operation.

    Patent expiration dates:

    • September 11, 2025
      ✓ 
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide